VNDA Stock Analysis: Vanda Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 308m USD | 12M Return: 16.4% | US9216591084 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.75M
Qual. Beats: -1
Rev. Trend: 66.7%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a U.S.-based, small-cap biopharmaceutical company headquartered in Washington, D.C., incorporated in 2002 and listed on NASDAQ since 2006. It focuses on developing and commercializing therapies for high unmet medical needs globally, operating within the biotechnology sub-industry of the healthcare sector.
The companys commercial portfolio spans neurology, psychiatry, and sleep disorders, including Fanapt (schizophrenia and bipolar I disorder), HETLIOZ (non-24-hour sleep-wake disorder and sleep disturbances), PONVORY (relapsing multiple sclerosis), and NEREUS (motion-induced vomiting). Beyond marketed products, Vanda has a diversified pipeline exploring expanded indications for existing assets, such as HETLIOZ for jet lag and insomnia, alongside earlier-stage candidates like Imsidolimab (an IL-36R antagonist for inflammatory skin conditions), VTR-297 (hematologic malignancies and oncology), and VQW-765 (a nicotinic receptor agonist for anxiety and psychiatric disorders).
The business model is typical of clinical-stage and commercial biopharma firms: revenue is generated from a limited set of approved specialty drugs, while a significant portion of resources is directed toward R&D to expand indications and advance pipeline candidates. Like many small-cap biotechs, Vandas valuation tends to reflect pipeline and regulatory milestones rather than stable, diversified revenue streams.
- Fanapt LAI formulation FDA approval expands schizophrenia market
- HETLIOZ patent litigation defends against generic competition
- Tradipitant GLP-1 side effect opportunity targets large adjacent market
| Net Income: -274.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.47 > 0.02 and ΔFCF/TA -36.35 > 1.0 |
| NWC/Revenue: 46.57% < 20% (prev 134.4%; Δ -87.82% < -1%) |
| CFO/TA -0.47 > 3% & CFO -192.5m > Net Income -274.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.2m) vs 12m ago 2.09% < -2% |
| Gross Margin: 92.82% > 18% (prev 93.54%; Δ -0.72% > 0.5%) |
| Asset Turnover: 41.60% > 50% (prev 32.57%; Δ 9.03% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.24 (Total Current Assets 264.5m - Total Current Liabilities 164.0m) / Total Assets 412.5m |
| B: -1.23 (Retained Earnings -505.8m / Total Assets 412.5m) |
| C: -0.35 (EBIT TTM -180.1m / Avg Total Assets 518.6m) |
| D: 1.15 (Book Value of Equity 220.2m / Total Liabilities 192.3m) |
| Altman-Z'' = -3.53 = D |
| DSRI: 1.25 (Receivables 59.7m/45.0m, Revenue 215.7m/203.5m) |
| GMI: 1.01 (GM 93.54% / 92.82%) |
| AQI: 0.86 (AQ_t 0.30 / AQ_t-1 0.35) |
| SGI: 1.06 (Revenue 215.7m / 203.5m) |
| TATA: -0.20 (NI -274.9m - CFO -192.5m) / TA 412.5m) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of September 18, 2026, the stock is trading at USD 5.11 with a total of 646,827 shares traded. Over the past week, the price has changed by +1.39%, over one month by -2.85%, over three months by -14.26% and over the past year by +16.40%.
Current recommended Stop Loss: 4.80 (which is 6.1% or 1.6 ATR below the current price).
Vanda Pharmaceuticals has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy VNDA.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.2 | 138.6% |
P/E Forward = 103.0928
P/S = 1.4266
P/B = 1.395
P/EG = 2.2319
Revenue TTM = 215.7m USD
EBIT TTM = -180.1m USD
EBITDA TTM = -166.6m USD
Long Term Debt = 18.2m USD (estimated: total debt 22.8m - short term 4.63m)
Short Term Debt = 4.63m USD (from shortTermDebt, last quarter)
Debt = 22.8m USD (from shortLongTermDebtTotal, last quarter) (leases 22.8m already included)
Net Debt = -147.2m USD (calculated: Debt 22.8m - CCE 170.0m)
Enterprise Value = 160.6m USD (307.8m + Debt 22.8m - CCE 170.0m)
Interest Coverage Ratio = unknown (Ebit TTM -180.1m / Interest Expense TTM 0.0)
EV/FCF = -0.83x (Enterprise Value 160.6m / FCF TTM -193.4m)
FCF Yield = -120.5% (FCF TTM -193.4m / Enterprise Value 160.6m)
FCF Margin = -89.67% (FCF TTM -193.4m / Revenue TTM 215.7m)
Net Margin = -127.4% (Net Income TTM -274.9m / Revenue TTM 215.7m)
Gross Margin = 92.82% ((Revenue TTM 215.7m - Cost of Revenue TTM 15.5m) / Revenue TTM)
Gross Margin QoQ = 92.95% (prev 90.05%)
Tobins Q-Ratio = 0.39 (Enterprise Value 160.6m / Total Assets 412.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 22.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -142.2m (EBIT -180.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.61 (Total Current Assets 264.5m / Total Current Liabilities 164.0m)
Debt / Equity = 0.10 (Debt 22.8m / totalStockholderEquity, last quarter 220.2m)
Debt / EBITDA = 0.88 (negative EBITDA) (Net Debt -147.2m / EBITDA -166.6m)
Debt / FCF = 0.76 (negative FCF - burning cash) (Net Debt -147.2m / FCF TTM -193.4m)
Total Stockholder Equity = 323.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.00% (Net Income -274.9m / Total Assets 412.5m)
RoE = -84.95% (Net Income TTM -274.9m / Total Stockholder Equity 323.5m)
RoCE = -52.69% (EBIT -180.1m / Capital Employed (Equity 323.5m + L.T.Debt 18.2m))
RoIC = -58.71% (negative operating profit) (NOPAT -142.2m / Invested Capital 242.3m)
WACC = 6.25% (E(307.8m)/V(330.6m) * Re(6.71%) + D(22.8m)/V(330.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 6.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.34 | Cagr: 1.88%
[DCF] Fair Price = unknown (Cash Flow -193.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.33 | # QB: -1
Revenue Correlation: 66.71 | Revenue CAGR: 5.23% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=-0.68 | Chg30d=-33.00% | Revisions=-57% | Analysts=4
EPS current Year (2026-12-31): EPS=-3.02 | Chg30d=-33.08% | Revisions=-57% | GrowthEPS=+19.3% | GrowthRev=+15.1%
EPS next Year (2027-12-31): EPS=-1.03 | Chg30d=-33.77% | Revisions=-29% | GrowthEPS=+65.9% | GrowthRev=+35.5%
[Analyst] Revisions Ratio: -67% (up=1, down=11)